WEE1 INHIBITORS AND METHODS FOR TREATING CANCER

Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered function of CCN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SAMATAR, Ahmed, LIU, Wen, DONATE, Fernando, BUNKER, Kevin, HUANG, Peter, PULTAR, Philippe, ESCOUBET, Laure, DE JONG, Petrus, VOLIOTIS, Dimitrios
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered function of CCNE1. Also disclosed are methods of treating cancer with a WEE1 inhibitor, comprising identifying a subject having (a) the cancer and (b) endogenous or altered function of CCNE1; and administering an effective amount of the WEE1 inhibitor, or a pharmaceutically acceptable salt thereof, to the subject. L'invention concerne une méthode de détermination de la sensibilité d'un sujet à un inhibiteur de WEE1, consistant à obtenir ou ayant obtenu un échantillon biologique provenant du sujet, et à réaliser ou à avoir exécuté au moins un dosage sur l'échantillon biologique pour déterminer si le sujet présente une fonction modifiée de CCNE1. L'invention concerne également des méthodes de traitement du cancer avec un inhibiteur de WEE1, comprenant l'identification d'un sujet ayant (a) le cancer et (b) la fonction endogène ou modifiée de CCNE1 ; et l'administration d'une quantité efficace de l'inhibiteur de WEE1, ou d'un sel pharmaceutiquement acceptable de celui-ci, au sujet.